Comparative Pharmacology
Head-to-head clinical analysis: THYROLAR 5 versus TRIOSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: THYROLAR 5 versus TRIOSTAT.
THYROLAR-5 vs TRIOSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thyrolar-5 is a combination of levothyroxine (T4) and liothyronine (T3), synthetic thyroid hormones. T4 is converted to T3 in peripheral tissues. T3 binds to thyroid hormone receptors, regulating gene transcription and increasing cellular metabolism.
TRIOSTAT (liothyronine sodium) is a synthetic form of the thyroid hormone triiodothyronine (T3). It binds to thyroid hormone receptors in the nucleus, altering gene expression and increasing cellular metabolism, oxygen consumption, and heat production.
Oral, starting dose 15-30 mg daily, titrated to maintenance dose of 60-120 mg daily, divided into 2-3 doses.
Adult: 5 mcg/kg IV every 8 hours. Adjust based on clinical response.
None Documented
None Documented
Liothyronine (T3): 1-2 days; Levothyroxine (T4): 6-7 days. Clinical context: In hyperthyroidism, T4 half-life shortens to 3-4 days; in hypothyroidism, prolongs to 9-10 days
2.5 days (terminal); shortened in hyperthyroidism, prolonged in hypothyroidism
Renal: 40-50% (as conjugated metabolites); Fecal: 20-30% (enterohepatic recirculation); Biliary: minor
Renal (40% unchanged, 20% as liothyronine conjugates); fecal (35%)
Category C
Category C
Thyroid Hormone
Thyroid Hormone